The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00719134
Recruitment Status :
First Posted : July 21, 2008
Results First Posted : April 9, 2015
Last Update Posted : April 9, 2015
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
Rami Burstein, Beth Israel Deaconess Medical Center
Of 98 persons pre-screened for eligibility between December 2008 and March 2010, 19 were excluded and 3 declined to participate. The remaining 76 persons signed the consent form, but 10 of them dropped out of the study for various reasons. Participants were recruited from Beth Israel Deaconess Medical Center outpatient clinics.
Reasons for excluding 19 of the pre-screened subjects include chronic migraine, chronic daily headache, tension type headache, fibromyalgia, daily use of opioids, and medication overuse headache. We randomized participants to one of 8 treatment sequences and each patient received 3 treatments with Maxalt and 3 treatments with Placebo.
76 subjects were randomized to 8 di...
76 subjects were randomized to 8 different treatment sequences. Each sequience included treating 6 attacks. 66 subjects completed their treatment assignment.